Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2010

Open Access 01-12-2010 | Research article

Neuroprotective properties of levosimendan in an in vitro model of traumatic brain injury

Authors: Anna B Roehl, Marc Hein, Philipp D Loetscher, Jan Rossaint, Joachim Weis, Rolf Rossaint, Mark Coburn

Published in: BMC Neurology | Issue 1/2010

Login to get access

Abstract

Background

We investigated the neuroprotective properties of levosimendan, a novel inodilator, in an in vitro model of traumatic brain injury.

Methods

Organotypic hippocampal brain slices from mouse pups were subjected to a focal mechanical trauma. Slices were treated after the injury with three different concentrations of levosimendan (0.001, 0.01 and 0.1 μM) and compared to vehicle-treated slices. After 72 hrs, the trauma was quantified using propidium iodide to mark the injured cells.

Results

A significant dose-dependent reduction of both total and secondary tissue injury was observed in cells treated with either 0.01 or 0.1 μM levosimendan compared to vehicle-treated slices.

Conclusion

Levosimendan represents a promising new pharmacological tool for neuroprotection after brain injury and warrants further investigation in an in vivo model.
Appendix
Available only for authorised users
Literature
1.
Abdel-Hamid KM, Tymianski M: Mechanisms and effects of intracellular calcium buffering on neuronal survival in organotypic hippocampal cultures exposed to anoxia/aglycemia or to excitotoxins. J Neurosci. 1997, 17: 3538-53.PubMed
2.
Loetscher PD, Rossaint J, Rossaint R, Weis J, Fries M, Fahlenkamp A, Ryang YM, Grottke O, Coburn M: Argon: Neuroprotection in in vitro models of cerebral ischemia and traumatic brain injury. Crit Care. 2009, 13: R206-10.1186/cc8214.CrossRefPubMedPubMedCentral
3.
Moppett IK: Traumatic brain injury: assessment, resuscitation and early management. Br J Anaesth. 2007, 99: 18-31. 10.1093/bja/aem128.CrossRefPubMed
4.
Shimizu K, Lacza Z, Rajapakse N, Horiguchi T, Snipes J, Busija DW: MitoK(ATP) opener, diazoxide, reduces neuronal damage after middle cerebral artery occlusion in the rat. Am J Physiol Heart Circ Physiol. 2002, 283: H1005-11.CrossRefPubMed
5.
Koudouna E, Xanthos T, Bassiakou E, Goulas S, Lelovas P, Papadimitriou D, Tsirikos N, Papadimitriou L: Levosimendan improves the initial outcome of cardiopulmonary resuscitation in a swine model of cardiac arrest. Acta Anaesthesiol Scand. 2007, 51: 1123-9. 10.1111/j.1399-6576.2007.01383.x.CrossRefPubMed
6.
Lafci B, Yasa H, Ilhan G, Ortac R, Yilik L, Kestelli M, Goktogan T, Gurbuz A: Protection of the spinal cord from ischemia: comparative effects of levosimendan and iloprost. Eur Surg Res. 2008, 41: 1-7. 10.1159/000121394.CrossRefPubMed
7.
Leker RR, Shohami E: Cerebral ischemia and trauma-different etiologies yet similar mechanisms: neuroprotective opportunities. Brain Res Brain Res Rev. 2002, 39: 55-73. 10.1016/S0165-0173(02)00157-1.CrossRefPubMed
8.
Coburn M, Maze M, Franks NP: The neuroprotective effects of xenon and helium in an in vitro model of traumatic brain injury. Crit Care Med. 2008, 36: 588-95. 10.1097/01.CCM.0B013E3181611F8A6.CrossRefPubMed
9.
Rossaint J, Rossaint R, Weis J, Fries M, Rex S, Coburn M: Propofol: neuroprotection in an in vitro model of traumatic brain injury. Crit Care. 2009, 13: R61-10.1186/cc7795.CrossRefPubMedPubMedCentral
10.
Noraberg J, Kristensen BW, Zimmer J: Markers for neuronal degeneration in organotypic slice cultures. Brain Res Brain Res Protoc. 1999, 3: 278-90. 10.1016/S1385-299X(98)00050-6.CrossRefPubMed
11.
Hein M, Roehl AB, Baumert JH, Scherer K, Steendijk P, Rossaint , R.Hein M, Roehl A, Rossaint R: Anti-ischemic effects of inotropic agents in experimental right. Acta Anaesthesiol Scand. 2009, 53: 941-8. 10.1111/j.1399-6576.2009.01994.x.CrossRefPubMed
Metadata
Title
Neuroprotective properties of levosimendan in an in vitro model of traumatic brain injury
Authors
Anna B Roehl
Marc Hein
Philipp D Loetscher
Jan Rossaint
Joachim Weis
Rolf Rossaint
Mark Coburn
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2010
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/1471-2377-10-97

Other articles of this Issue 1/2010

BMC Neurology 1/2010 Go to the issue

Research article

Evidence based guidelines for complex regional pain syndrome type 1

Study protocol

Multi-centre parallel arm randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based cognitive behavioural approach to managing fatigue in people with multiple sclerosis

Study protocol

Modified constraint-induced movement therapy or bimanual occupational therapy following injection of Botulinum toxin-A to improve bimanual performance in young children with hemiplegic cerebral palsy: a randomised controlled trial methods paper

Research article

Is elevated SUA associated with a worse outcome in young Chinese patients with acute cerebral ischemic stroke?

Research article

Mutational spectrum of the SPG4 (SPAST) and SPG3A (ATL1) genes in Spanish patients with hereditary spastic paraplegia

Research article

Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch